Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Karyopharm Therapeutics Inc. | d113778d10k.htm |
| EX-32.1 - EX-32.1 - Karyopharm Therapeutics Inc. | d113778dex321.htm |
| EX-23.2 - EX-23.2 - Karyopharm Therapeutics Inc. | d113778dex232.htm |
| EX-21.1 - EX-21.1 - Karyopharm Therapeutics Inc. | d113778dex211.htm |
| EX-31.1 - EX-31.1 - Karyopharm Therapeutics Inc. | d113778dex311.htm |
| EX-12.1 - EX-12.1 - Karyopharm Therapeutics Inc. | d113778dex121.htm |
| EX-31.2 - EX-31.2 - Karyopharm Therapeutics Inc. | d113778dex312.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statement (Form S-3 No. 333-201366) of Karyopharm Therapeutics Inc., |
| (2) | Registration Statement (Form S-8 No. 333-194746) of Karyopharm Therapeutics Inc., and |
| (3) | Registration Statement (Form S-8 No. 333-202742) of Karyopharm Therapeutics Inc., |
of our report dated March 15, 2016, with respect to the consolidated financial statements of Karyopharm Therapeutics Inc. included in this Annual Report (Form 10-K) of Karyopharm Therapeutics Inc. for the year ended December 31, 2015.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 15, 2016